Cormorant Asset Management, LP Karuna Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$164.66 - $218.08 $9.88 Million - $13.1 Million	60,000 Added 75.0%	140,000 $23.7 Million
Q1 2023 May 15, 2023	SELL	$161.33 - $204.36 $4.84 Million - $6.13 Million	-30,000 Reduced 27.27%	80,000 $14.5 Million
Q4 2022 Feb 14, 2023	SELL	$191.53 - $236.82 $7.66 Million - $9.47 Million	-40,000 Reduced 26.67%	110,000 $21.6 Million
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $3.09 Million - $6.94 Million	25,000 Added 20.0%	150,000 $33.7 Million
Q2 2022 Aug 15, 2022	SELL	$93.97 - $143.33 $2.35 Million - $3.58 Million	-25,000 Reduced 16.67%	125,000 $15.8 Million
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $14.8 Million - $19.9 Million	150,000 New	150,000 $19 Million

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.